Table 8.
Summary of the studies evaluating the cfDNA dynamics included in this paragraph
| Trial | First author | Disease context | Intervention control groups | cfDNA technique | Gene investigated |
|---|---|---|---|---|---|
| CAPRI-GOIM | F. Ciardiello | mCRC |
- FOLFOX + Cetuximab - FOLFOX |
NGS | KRAS/NRAS/BRAF/PIK3CA |
| ASPECCT | TJ. Price | mCRC |
- Panitumumab - Cetuximab |
BEAMing NGS | KRAS |
| CRICKET | C. Cremolini | mCRC | - Cetuximab + Irinotecan | ddPCR NGS | RAS/BRAF |
| CHRONOS | A. Sartore-Bianchi | mCRC | - Panitumumab | ddPCR NGS | RAS/BRAF/EGFR |
| CAPRI-2 | ongoing | mCRC |
- Cetuximab - FOLFIRI - FOLFOX regimen - Irinotecan |
NGS | RAS/BRAF |
| AURA-3 | TS Mok | mNSCLC T790M + |
- Osimertinib - Carboplatin + Pemetrexed |
NGS | EGFR |
| FLAURA | SS Ramalingam | mNSCLC |
- Osimertinib - Gefitinib - Erlotinib |
NGS | EGFR |
| NILE | RD Page | mNSCLC | / | NGS |
EGFR/ALK/ROS-1/BRAF MET/ERBB2/RET |
| BFAST | R Dziadziuszko | mNSCLC | - Alectinib | NGS | ALK |
| ALEX | TS Mok | mNSCLC |
- Alectinib - Crizotinib |
NGS | ALK |
| APPLE | J Remon |
mNSCLC EGFR + |
- Osimertinib - Gefitinib |
NGS | EGFR |
| / | C Aggarwal | mNSCLC | NGS–indicated therapy | NGS | EGFR/ALK/MET/BRCA1/ROS1/RET/ERBB2/BRAF |
| PALOMA-3 | O'Leary | mBC |
- Palbociclib + Fulvestrant - Placebo + fulvestrant |
NGS | RB1/ PIK3CA/ESR1 |
| PLASMA-MATCH | NC Turner | mBC |
- Fulvestrant - Neratinib - Capivasertib |
NGS | AKT1/HER2/PTEN/ESR1 |
Abbreviations: mCRC metastatic colorectal cancer, NGS Next-generation sequencing, FOLFOX 5-fluorouracil/leucovorin combined with oxaliplatin, KRAS Kirsten RAt Sarcoma virus, NRAS Neuroblastoma ras viral oncogene, BRAF v-raf murine sarcoma viral oncogene, PIK3CA Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha, BEAMing Beads, emulsion, amplification, magnetics, ddPCR droplet digital polymerase chain reaction, EGFR Epidermal growth factor receptor, mNSCLC metastatic Non-Small Cell Lung Cancer, ALK Anaplastic lymphoma kinase, ROS-1 ROS Proto-Oncogene 1, MET Mesenchymal Epithelial Transition, ERBB2 Erythroblastic oncogene B, RET Rearranged during transfection, mBC metastatic breast cancer, RB1 Retinoblastoma protein 1, ESR1 Estrogen Receptor 1, AKT1 AKT serine/threonine kinase 1, HER2 Human epidermal growth factor receptor 2, PTEN Phosphatase and tensin homolog